The University of Chicago Header Logo

Connection

Richard A. Larson to Acute Disease

Back to Details
This is a "connection" page, showing publications Richard A. Larson has written about Acute Disease.
Richard A. Larson
Connection Strength
1.195
Acute Disease
  1. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Best Pract Res Clin Haematol. 2007 Mar; 20(1):29-37.
    View in: PubMed
    Score: 0.064
  2. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. Chem Biol Interact. 2005 May 30; 153-154:187-95.
    View in: PubMed
    Score: 0.056
  3. Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia? Leukemia. 2003 Mar; 17(3):488-91.
    View in: PubMed
    Score: 0.049
  4. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228.
    View in: PubMed
    Score: 0.047
  5. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia. 2002 Sep; 16(9):1627-36.
    View in: PubMed
    Score: 0.047
  6. Myeloid leukemia after cytotoxic therapy and other hematotoxins. J Toxicol Environ Health A. 2000 Nov; 61(5-6):381-6.
    View in: PubMed
    Score: 0.041
  7. Long-term follow-up of Cancer and Leukemia Group B studies in acute myeloid leukemia. Cancer. 1997 Dec 01; 80(11 Suppl):2210-4.
    View in: PubMed
    Score: 0.034
  8. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood. 1996 Oct 01; 88(7):2665-70.
    View in: PubMed
    Score: 0.031
  9. miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat Commun. 2016 04 26; 7:11452.
    View in: PubMed
    Score: 0.030
  10. Treatment of acute myeloid leukemia with antecedent myelodysplastic syndrome. Leukemia. 1996 Apr; 10 Suppl 1:S23-5.
    View in: PubMed
    Score: 0.030
  11. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am. 1996 Apr; 10(2):293-320.
    View in: PubMed
    Score: 0.030
  12. Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia. Leukemia. 1995 Mar; 9(3):433-9.
    View in: PubMed
    Score: 0.028
  13. Acute leukemia in adults: recent developments in diagnosis and treatment. CA Cancer J Clin. 1994 Nov-Dec; 44(6):326-52.
    View in: PubMed
    Score: 0.027
  14. Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol. 2014 Nov; 74(5):927-38.
    View in: PubMed
    Score: 0.027
  15. The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study. Br J Haematol. 1992 Oct; 82(2):337-46.
    View in: PubMed
    Score: 0.024
  16. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.
    View in: PubMed
    Score: 0.023
  17. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood. 2012 Mar 08; 119(10):2314-24.
    View in: PubMed
    Score: 0.022
  18. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011 Dec 22; 118(26):6920-9.
    View in: PubMed
    Score: 0.022
  19. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010 Aug 05; 116(5):788-92.
    View in: PubMed
    Score: 0.020
  20. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1209-16.
    View in: PubMed
    Score: 0.018
  21. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8.
    View in: PubMed
    Score: 0.017
  22. Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy. Am J Med. 1988 Feb; 84(2):233-9.
    View in: PubMed
    Score: 0.017
  23. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood. 2007 Jun 15; 109(12):5164-7.
    View in: PubMed
    Score: 0.016
  24. A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. J Clin Oncol. 1987 Mar; 5(3):391-7.
    View in: PubMed
    Score: 0.016
  25. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol. 2007 Feb; 127(2):197-205.
    View in: PubMed
    Score: 0.016
  26. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood. 2007 Mar 01; 109(5):1810-6.
    View in: PubMed
    Score: 0.016
  27. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006 Aug 20; 24(24):3904-11.
    View in: PubMed
    Score: 0.015
  28. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood. 2006 Sep 01; 108(5):1677-83.
    View in: PubMed
    Score: 0.015
  29. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia. 2006 Jul; 20(7):1295-7.
    View in: PubMed
    Score: 0.015
  30. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006 Jul 01; 108(1):63-73.
    View in: PubMed
    Score: 0.015
  31. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Dec 20; 23(36):9234-42.
    View in: PubMed
    Score: 0.015
  32. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Aug 20; 23(24):5705-17.
    View in: PubMed
    Score: 0.014
  33. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38.
    View in: PubMed
    Score: 0.014
  34. Use of decline in D-xylose absorption to predict infection following intensive chemotherapy. Cancer Treat Rep. 1984 Dec; 68(12):1489-91.
    View in: PubMed
    Score: 0.014
  35. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005 May 01; 105(9):3420-7.
    View in: PubMed
    Score: 0.014
  36. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol. 2005 Jan 20; 23(3):482-93.
    View in: PubMed
    Score: 0.014
  37. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol. 2004 Nov 01; 22(21):4290-301.
    View in: PubMed
    Score: 0.014
  38. Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. Cancer. 2004 Sep 15; 101(6):1420-7.
    View in: PubMed
    Score: 0.014
  39. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. J Clin Oncol. 2004 Jun 15; 22(12):2410-8.
    View in: PubMed
    Score: 0.013
  40. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004 Mar 15; 22(6):1087-94.
    View in: PubMed
    Score: 0.013
  41. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes Cancer. 2004 Mar; 39(3):217-23.
    View in: PubMed
    Score: 0.013
  42. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004 Jun 01; 103(11):4036-42.
    View in: PubMed
    Score: 0.013
  43. P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults. Ann Hematol. 2004; 83 Suppl 1:S103-4.
    View in: PubMed
    Score: 0.013
  44. The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: a 12-year study (1970-1982). Cancer Genet Cytogenet. 1983 Nov; 10(3):219-36.
    View in: PubMed
    Score: 0.013
  45. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood. 2003 Sep 01; 102(5):1613-8.
    View in: PubMed
    Score: 0.012
  46. Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci U S A. 2002 Nov 12; 99(23):14925-30.
    View in: PubMed
    Score: 0.012
  47. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol. 2002 Sep 15; 20(18):3878-84.
    View in: PubMed
    Score: 0.012
  48. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin Cancer Res. 2002 Sep; 8(9):2812-9.
    View in: PubMed
    Score: 0.012
  49. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002 Dec 15; 100(13):4325-36.
    View in: PubMed
    Score: 0.012
  50. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001 Oct 01; 61(19):7233-9.
    View in: PubMed
    Score: 0.011
  51. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001 Jul 01; 19(13):3244-54.
    View in: PubMed
    Score: 0.011
  52. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics. 2001 Jan 15; 71(2):235-45.
    View in: PubMed
    Score: 0.010
  53. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000 Apr 15; 95(8):2530-5.
    View in: PubMed
    Score: 0.010
  54. dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53. Genes Chromosomes Cancer. 1997 Nov; 20(3):282-91.
    View in: PubMed
    Score: 0.008
  55. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood. 1996 Sep 15; 88(6):1930-5.
    View in: PubMed
    Score: 0.008
  56. Familial myeloid leukemia associated with loss of the long arm of chromosome 5. Leukemia. 1996 Apr; 10(4):669-74.
    View in: PubMed
    Score: 0.008
  57. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci U S A. 1993 Jun 15; 90(12):5484-8.
    View in: PubMed
    Score: 0.006
  58. Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study. Exp Hematol. 1992 Nov; 20(10):1194-200.
    View in: PubMed
    Score: 0.006
  59. t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 1990 Dec 15; 76(12):2594-8.
    View in: PubMed
    Score: 0.005
  60. Methyl transferase activity in secondary leukemia. Basic Life Sci. 1990; 53:277-89.
    View in: PubMed
    Score: 0.005
  61. Disseminated cutaneous and peritoneal hyalohyphomycosis caused by Fusarium species: three cases and review of the literature. Mycopathologia. 1988 Feb; 101(2):105-11.
    View in: PubMed
    Score: 0.004
  62. Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia. 1988 Feb; 2(2):79-83.
    View in: PubMed
    Score: 0.004
  63. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987 Nov; 70(5):1412-7.
    View in: PubMed
    Score: 0.004
  64. High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study. J Clin Oncol. 1987 Jan; 5(1):75-82.
    View in: PubMed
    Score: 0.004
  65. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol. 1986 Mar; 4(3):325-45.
    View in: PubMed
    Score: 0.004
  66. Limited efficacy of a four-day course of high-dose cytosine arabinoside in the treatment of poor-risk patients with acute nonlymphocytic leukemia. Cancer Chemother Pharmacol. 1986; 18(3):257-60.
    View in: PubMed
    Score: 0.004
  67. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. Cancer. 1985 Aug 01; 56(3):443-9.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.